The impact of changes in ASCO-CAP recommendations on the FISH-based assessment of the HER2 gene status in the qualification of breast cancer patients for HER2-targeted therapy
Abstract
Introduction. Breast cancer is the most common cancer among Polish women. Overexpression of the HER2 protein or HER2 gene amplification is associated with a poor prognosis, simultaneously being an indication for the HER2-targeted therapy. In equivocal cases, the FISH assay is used for the final identification of the HER2 gene status. This evaluation should be performed according to the ASCO-CAP guidelines which have been changed in 2013. The aim of this study was to assess whether and how the changes of recommendations affected the distribution of the FISH results.
Materials and methods. The results of routine diagnostic FISH analyses were compared for two independent groups of patients assessed with different evaluation criteria (ASCO-CAP 2007 for n = 680 and ASCO-CAP 2013 n = 851), and also in a group of 763 patients, where both criteria were used simultaneously.
Results. A comparison of the results obtained in two independent groups showed that the change of evaluation criteria did not alter the percentage of HER2-positive tests (with HER2 amplification). However, the frequency of HER2-negative analyses (without HER2 amplification) diminished significantly from 76.2% to 61.8%, whereas the equivocal group (with an indefinite status of HER2 amplification) increased from 0.4% to 13.6%. In the group where both criteria from 2007 and 2013 were used, we also discovered statistically significant differences. The frequency of HER2-positive results were elevated from 10.6% to 16.8%. The equivocal results were also found more often, rising from 4.2% to 15.6%, while the number of negative results lowered from 85.2% to 67.6%.
Conclusions. The use of ASCO/CAP recommendations for the assessment of the HER2 gene status reduces the group of negative results, and concurrently enlarges the number of positive and equivocal ones. This indicates that the new criteria extends the access to HER2-targeted therapy. Nevertheless, they also raise the frequency of analyses with an indefinite status of the HER2 gene. Our outcome suggests that there is a need for an enhanced FISH-based evaluation of this gene in the last group of patients in order to provide them with an unambiguous stratification to risk groups.